Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
NCT ID: NCT01586858
Last Updated: 2017-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
67 participants
OBSERVATIONAL
2012-05-31
2014-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RAVE subjects
Observational
Observational study of subjects previously enrolled in the RAVE trial
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational
Observational study of subjects previously enrolled in the RAVE trial
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Completion of RAVE Common Closeout Date visit
3. Informed consent
Exclusion Criteria
2. Inability to comply with standard-of-care, including routine clinical visits and testing.
12 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alabama at Birmingham
OTHER
Boston University
OTHER
Mayo Clinic
OTHER
Duke University
OTHER
The Cleveland Clinic
OTHER
University Medical Center Groningen
OTHER
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip Seo, MD
Role: STUDY_DIRECTOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Johns Hopkins University
Baltimore, Maryland, United States
Boston University
Boston, Massachusetts, United States
Mayo Clinic Foundation
Rochester, Minnesota, United States
Hospital for Special Surgery
New York, New York, United States
Duke University
Durham, North Carolina, United States
The Cleveland Clinic
Cleveland, Ohio, United States
University Hospital Groningen
Groningen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML27815
Identifier Type: -
Identifier Source: org_study_id